StockNews.com initiated coverage on shares of Aptose Biosciences (NASDAQ:APTO – Free Report) (TSE:APS) in a research report sent to investors on Thursday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
A number of other brokerages have also issued reports on APTO. HC Wainwright reissued a buy rating and set a $7.00 target price on shares of Aptose Biosciences in a research note on Friday, June 14th. Piper Sandler reaffirmed an overweight rating and issued a $5.00 price objective on shares of Aptose Biosciences in a research note on Wednesday, April 3rd. Finally, Canaccord Genuity Group reduced their price objective on shares of Aptose Biosciences from $15.00 to $6.00 and set a buy rating for the company in a research note on Thursday, May 16th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of Moderate Buy and an average price target of $14.83.
View Our Latest Report on APTO
Aptose Biosciences Stock Down 6.5 %
Aptose Biosciences (NASDAQ:APTO – Get Free Report) (TSE:APS) last issued its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.09. Equities research analysts expect that Aptose Biosciences will post -2.62 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Aptose Biosciences stock. Texas Capital Bank Wealth Management Services Inc bought a new position in Aptose Biosciences Inc. (NASDAQ:APTO – Free Report) (TSE:APS) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 12,448 shares of the biotechnology company’s stock, valued at approximately $32,000. Texas Capital Bank Wealth Management Services Inc owned 0.16% of Aptose Biosciences at the end of the most recent reporting period. Institutional investors and hedge funds own 26.62% of the company’s stock.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Featured Stories
- Five stocks we like better than Aptose Biosciences
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.